QuidelOrtho's (QDEL) New Test to Offer Enhanced Opioid Testing
https://www.zacks.com/stock/news/2254708/quidelortho-s-qdel-new-test-to-offer-enhanced-opioid-testing?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2254708
Apr 12, 2024 - QuidelOrtho's (QDEL) addition of the Fentanyl Test is likely to deliver rapid drugs-of-abuse detection amidst the escalating opioid crisis.
0
Baxter's (BAX) New Injectables Aid Its Pharmaceutical Portfolio
https://www.zacks.com/stock/news/2254665/baxter-s-bax-new-injectables-aid-its-pharmaceutical-portfolio?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2254665
Apr 12, 2024 - Baxter (BAX) unveils its five injectable products, which strengthen its emphasis on unique products and expand the pharmaceutical portfolio of the business in important therapeutic areas.
0
Hologic's (HOLX) New Launches Aid, Macroeconomic Issues Ail
https://www.zacks.com/stock/news/2254645/hologic-s-holx-new-launches-aid-macroeconomic-issues-ail?cid=CS-ZC-FT-analyst_blog|zer_report_update-2254645
Apr 12, 2024 - Hologic's (HOLX) Breast Health segment is gaining from a broad portfolio of solutions for breast cancer care, primarily in the burgeoning spaces of radiology, breast surgery, pathology and treatment.
0
Reasons to Hold The Cooper Companies (COO) in Your Portfolio Now
https://www.zacks.com/stock/news/2254630/reasons-to-hold-the-cooper-companies-coo-in-your-portfolio-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2254630
Apr 12, 2024 - The Cooper Companies (COO) benefits from strength in its business segments. Its acquisitions are likely to drive the top line. A rise in selling, general and administrative expenses is concerning.
0
3 Medical Device Stocks With Solid Dividend Yield: CAH & Others
https://www.zacks.com/stock/news/2253901/3-medical-device-stocks-with-solid-dividend-yield-cah-others?cid=CS-ZC-FT-analyst_blog|industry_focus-2253901
Apr 11, 2024 - Here we discuss three medical device stocks, Cardinal Health (CAH), Baxter International (BAX) and Fresenius Medical Care (FMS), with a solid five-year dividend growth history.
0
Reasons to Retain Fresenius Medical (FMS) in Your Portfolio Now
https://www.zacks.com/stock/news/2253436/reasons-to-retain-fresenius-medical-fms-in-your-portfolio-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2253436
Apr 10, 2024 - Fresenius Medical (FMS) continues to gain traction through its broad dialysis product and service portfolio. Intense competition is a woe.
0
Here's Why You Should Retain Merit Medical (MMSI) Stock for Now
https://www.zacks.com/stock/news/2253435/here-s-why-you-should-retain-merit-medical-mmsi-stock-for-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2253435
Apr 10, 2024 - Merit Medical's (MMSI) strong product portfolio raises optimism about the stock.
0
Why You Should Retain Integer Holdings (ITGR) Stock for Now
https://www.zacks.com/stock/news/2252801/why-you-should-retain-integer-holdings-itgr-stock-for-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2252801
Apr 09, 2024 - Integer Holdings' (ITGR) research and product development activities raise optimism about the stock.
0
Why You Should Retain Inari Medical (NARI) Stock for Now
https://www.zacks.com/stock/news/2252746/why-you-should-retain-inari-medical-nari-stock-for-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2252746
Apr 09, 2024 - Inari Medical (NARI) continues to gain from its expanded product portfolio. However, continued loss at the operating level raises concern.
0
Here's Why You Should Retain Myriad Genetics (MYGN) Stock Now
https://www.zacks.com/stock/news/2252692/here-s-why-you-should-retain-myriad-genetics-mygn-stock-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2252692
Apr 09, 2024 - Investors are optimistic about Myriad Genetics' (MYGN) strong solvency position and improvement in testing volume.
0